...vice president of marketing and business affairs in August 2000. He had been in various management positions at Bristol-Myers Squibb Co. from 1997 to 2000. For six years before that, Shah was with Roche, including time as global business leader for oncology...

...a fly on the wall in Kindler's office. Jim Cramer raises some analysts' favorite pick: Amgen. He adds Gilead Science, Bristol-Myers Squibb and Wyeth to his list of possibilities. Why? These companies could "boost its biotech street credibility" and/or add...

...I'd be itching to make a purchase. But Pfizer has showed restraint by, for instance, not jumping into a bidding war with Bristol-Myers Squibb (NYSE: BMY) and Eli Lilly (NYSE: LLY) over ImClone Systems. Based on Kindler's statements, I expect it'll do the same...

...Co., Ltd. -- Hebei Jiheng (Group) Pharmacy Co., Ltd. -- Shanghai Johnson-Johnson Pharmaceuticals, Ltd. -- Bristol-Myers Squibb Company Source: Research and Markets Paracetamol, which takes the most important position among NSAIDs,...

...improve cash flow up to $1 billion cumulatively by 2011 through better inventory, receivables, and payables controls. "Bristol-Myers Squibb boosted its dividend nearly 11% at the beginning of this year. Even if the company doesn't raise its dividend in 2009,...

...its portfolio by acquiring strategic products and subsidiaries in particular regions from rivals AstraZeneca and Bristol-Myers Squibb . Bankers, keen for important mandates at a time when deal flow has been drying up, predict a return to large industry deals,...

...drugmakers have shed thousands of reps--Merck, GlaxoSmithKline, Schering-Plough, Wyeth, Novartis, Sanofi-Aventis, Bristol-Myers Squibb--often reorganizing those who remain. The reps who have kept their jobs are facing constraints out in the field. Concerned...

...intact barring a violation of its 50-day moving average. The charts below illustrate related names positioned to rise: Bristol-Myers Squibb BMY (yield = 5.5%), Novartis AG NVS (yield = 3.0%), and GlaxoSmithKline GSK (yield = 5.1%). Group #3: China not immune...

...treatments. He has introduced development projects where the risk is shared with others, including a joint project with Bristol Myers Squibb on Apixaban to prevent blood clots. But he stresses that Pfizer has also invested, expanding into vaccines and biological...

...our cake toppers were a Tiger and a Scarlet Knight," says Yodice, who, along with her husband, works in sales at Bristol-Myers Squibb. "We even had specialty drinks during our cocktail hour called Tigertinis and Scarlet Knights!" One-hundred-seventy guests...